Brief: Sesen Bio Inc - $161 Million In Cash, Cash Equivalents And Marketable Securities As Of June 30, 2022

Carisma Therapeutics

08/08/2022 13:23

Aug 8 (Reuters) - Sesen Bio Inc  SESN.O :
    * SESEN BIO REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS
AND
BUSINESS UPDATE
    * SESEN BIO INC - $161 MILLION IN CASH, CASH EQUIVALENTS AND
MARKETABLE SECURITIES AS OF JUNE 30, 2022
    * SESEN BIO INC - NET LOSS WAS $32.0 MILLION, OR $0.16 PER
BASIC
AND PER DILUTED SHARE, FOR Q2 OF 2022

Source text for Eikon:  ID:nBw1XrSQja 
Further company coverage:  SESN.O 

 ((Reuters.Briefs@thomsonreuters.com;))